EMD Millipore’s Discovery and Development Solutions business offers genomic biomarker services to aid drug companies in targeting patient sub-groups for improved clinical outcomes, understanding drug safety and efficacy and characterizing tumors. The qPCR and pyrosequencing-based services add to the company’s existing protein- and cell-based solutions, which include ELISA, multiplex and flow cytometry platforms, as well as its experience in assay development, validation and sample testing. By enabling both genomic biomarker analysis as well as cross-platform biomarker validation, the company can help customers improve their research and development pipeline decisions. Demonstrating the value of the biomarker services, which now links genomic, protein-based and cell-based technologies, scientists at the company recently profiled transcription in gefitinib-treated non-small cell lung cancer cells by qRT-PCR. The genotypic and mRNA expression data were then cross-validated with protein expression using flow cytometry and multiplex assays, solidifying the connection between the genotype and phenotype of interest. These types of connections provide confidence to preclinical and clinical decision makers regarding drug safety and efficacy.